8-K: Alpha Cognition Announces Board Changes: John Havens to Depart, Robert Wills Appointed

Alpha Cognition Inc. reports the departure of John Havens from the Board of Directors and the appointment of Robert Wills, Ph.D., effective April 7, 2025.

Summary

• On April 7, 2025, John Havens informed Alpha Cognition Inc. of his decision not to seek re-election to the Board of Directors at the company's annual meeting.
• The company appointed Robert Wills, Ph.D., to the Board and Governance and Nominating Committee, effective April 7, 2025.
• Dr. Wills brings extensive experience in the pharmaceutical and biotechnology industries.
• He will receive an annual base salary of $40,000 for his Board membership and an additional $5,000 annually for his service on the Governance and Nominating Committee.
• Dr. Wills also received an initial grant of 35,575 stock options at an exercise price of $4.83 per share, vesting over 24 months.

Sentiment

Score: 7

Explanation: The announcement is neutral to positive. The departure of a board member is offset by the appointment of an experienced professional, suggesting a stable transition and continued focus on growth.

Positives

• The appointment of Robert Wills, Ph.D., brings significant pharmaceutical and biotechnology experience to Alpha Cognition's Board.
• Dr. Wills' extensive background in drug development, corporate strategy, and executive leadership could benefit the company.
• The stock option grant aligns Dr. Wills' interests with those of the shareholders.

Industry Context

Changes in board composition are common in the pharmaceutical and biotechnology industries as companies seek expertise to guide drug development and corporate strategy. The appointment of Dr. Wills, with his extensive experience, aligns with this trend.

Comparison to Industry Standards

• Compensation for board members in similar Nasdaq-listed biotech companies typically includes a base salary and stock options.
• The annual base salary of $40,000 for Dr. Wills is within the range of compensation for non-executive directors in comparable companies.
• The vesting schedule of the stock options (12.5% on the grant date and 12.5% per quarter thereafter) is a standard practice to incentivize long-term commitment.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of Dr. Wills positively, given his extensive experience in the pharmaceutical industry.
• The changes are unlikely to have a significant impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Board of Directors, Robert Wills, John Havens, Appointment, Departure, Governance, Nominating Committee, Stock Options, Pharmaceutical, Biotechnology, ACOG, Alpha Cognition